25 XP   0   0   10

I-Mab
Buy, Hold or Sell?

Let's analyse I-Mab together

PenkeI guess you are interested in I-Mab. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of I-Mab. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about I-Mab

I send you an email if I find something interesting about I-Mab.

Quick analysis of I-Mab (30 sec.)










What can you expect buying and holding a share of I-Mab? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
33.3%

What is your share worth?

Current worth
$5.03
Expected worth in 1 year
$-6.23
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-11.26
Return On Investment
-625.8%

For what price can you sell your share?

Current Price per Share
$1.80
Expected price per share
$1.63 - $1.94
How sure are you?
50%

1. Valuation of I-Mab (5 min.)




Live pricePrice per Share (EOD)

$1.80

Intrinsic Value Per Share

$-18.01 - $-14.49

Total Value Per Share

$-12.97 - $-9.46

2. Growth of I-Mab (5 min.)




Is I-Mab growing?

Current yearPrevious yearGrowGrow %
How rich?$415.4m$633.5m-$218.1m-52.5%

How much money is I-Mab making?

Current yearPrevious yearGrowGrow %
Making money-$333m-$321.9m-$11m-3.3%
Net Profit Margin1,088.5%-2,648.7%--

How much money comes from the company's main activities?

3. Financial Health of I-Mab (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of I-Mab? (5 min.)

Welcome investor! I-Mab's management wants to use your money to grow the business. In return you get a share of I-Mab.

What can you expect buying and holding a share of I-Mab?

First you should know what it really means to hold a share of I-Mab. And how you can make/lose money.

Speculation

The Price per Share of I-Mab is $1.8. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of I-Mab.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in I-Mab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.03. Based on the TTM, the Book Value Change Per Share is $-2.82 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.78 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of I-Mab.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-4.04-224.2%-4.04-224.2%-3.99-221.7%-2.09-116.1%-1.83-101.5%
Usd Book Value Change Per Share-2.82-156.4%-2.82-156.4%-1.78-98.8%1.1161.6%0.8446.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.3%0.000.2%
Usd Total Gains Per Share-2.82-156.4%-2.82-156.4%-1.78-98.8%1.1161.9%0.8446.8%
Usd Price Per Share4.18-4.18-47.39-19.74-16.45-
Price to Earnings Ratio-1.04--1.04--11.88-9.12-7.60-
Price-to-Total Gains Ratio-1.48--1.48--26.64--8.18--8.18-
Price to Book Ratio0.83-0.83-6.04-2.35-1.96-
Price-to-Total Gains Ratio-1.48--1.48--26.64--8.18--8.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.8
Number of shares555
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.821.11
Usd Total Gains Per Share-2.821.11
Gains per Quarter (555 shares)-1,562.92618.58
Gains per Year (555 shares)-6,251.662,474.31
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-6252-62621124632464
20-12503-125142249264938
30-18755-187663373907412
40-25007-250184498539886
50-31258-31270551231612360
60-37510-37522671477914834
70-43762-43774781724317308
80-50013-50026891970619782
90-56265-562781002216922256
100-62517-625301112463224730

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.05.00.016.7%1.05.00.016.7%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.05.00.016.7%1.05.00.016.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%2.00.04.033.3%2.00.04.033.3%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.05.00.016.7%1.05.00.016.7%

Fundamentals of I-Mab

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-11 11:39:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of I-Mab.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit I-Mab earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare I-Mab to the Biotechnology industry mean.
  • A Net Profit Margin of 1,088.5% means that $10.89 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of I-Mab:

  • The MRQ is 1,088.5%. The company is making a huge profit. +2
  • The TTM is 1,088.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ1,088.5%TTM1,088.5%0.0%
TTM1,088.5%YOY-2,648.7%+3,737.2%
TTM1,088.5%5Y-1,425.6%+2,514.2%
5Y-1,425.6%10Y-1,618.2%+192.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1,088.5%-196.1%+1,284.6%
TTM1,088.5%-211.9%+1,300.4%
YOY-2,648.7%-277.7%-2,371.0%
5Y-1,425.6%-432.9%-992.7%
10Y-1,618.2%-599.3%-1,018.9%
1.1.2. Return on Assets

Shows how efficient I-Mab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare I-Mab to the Biotechnology industry mean.
  • -59.2% Return on Assets means that I-Mab generated $-0.59 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of I-Mab:

  • The MRQ is -59.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -59.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-59.2%TTM-59.2%0.0%
TTM-59.2%YOY-41.4%-17.8%
TTM-59.2%5Y-38.8%-20.4%
5Y-38.8%10Y-37.2%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-59.2%-13.3%-45.9%
TTM-59.2%-12.7%-46.5%
YOY-41.4%-11.8%-29.6%
5Y-38.8%-14.0%-24.8%
10Y-37.2%-15.9%-21.3%
1.1.3. Return on Equity

Shows how efficient I-Mab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare I-Mab to the Biotechnology industry mean.
  • -80.2% Return on Equity means I-Mab generated $-0.80 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of I-Mab:

  • The MRQ is -80.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -80.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-80.2%TTM-80.2%0.0%
TTM-80.2%YOY-50.8%-29.4%
TTM-80.2%5Y-24.5%-55.6%
5Y-24.5%10Y-20.4%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.2%-16.9%-63.3%
TTM-80.2%-16.0%-64.2%
YOY-50.8%-15.1%-35.7%
5Y-24.5%-19.7%-4.8%
10Y-20.4%-20.5%+0.1%

1.2. Operating Efficiency of I-Mab.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient I-Mab is operating .

  • Measures how much profit I-Mab makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare I-Mab to the Biotechnology industry mean.
  • An Operating Margin of 845.8% means the company generated $8.46  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of I-Mab:

  • The MRQ is 845.8%. The company is operating very efficient. +2
  • The TTM is 845.8%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ845.8%TTM845.8%0.0%
TTM845.8%YOY-2,353.1%+3,198.9%
TTM845.8%5Y-1,416.9%+2,262.7%
5Y-1,416.9%10Y-1,602.8%+185.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ845.8%-290.9%+1,136.7%
TTM845.8%-224.4%+1,070.2%
YOY-2,353.1%-288.3%-2,064.8%
5Y-1,416.9%-479.5%-937.4%
10Y-1,602.8%-625.2%-977.6%
1.2.2. Operating Ratio

Measures how efficient I-Mab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of -7.46 means that the operating costs are $-7.46 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of I-Mab:

  • The MRQ is -7.458.
  • The TTM is -7.458.
Trends
Current periodCompared to+/- 
MRQ-7.458TTM-7.4580.000
TTM-7.458YOY24.531-31.989
TTM-7.4585Y15.385-22.843
5Y15.38510Y17.040-1.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.4583.110-10.568
TTM-7.4583.266-10.724
YOY24.5313.783+20.748
5Y15.3855.657+9.728
10Y17.0407.783+9.257

1.3. Liquidity of I-Mab.

1.3. Liquidity
1.3.1. Current Ratio

Measures if I-Mab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.50 means the company has $5.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of I-Mab:

  • The MRQ is 5.497. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.497. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.497TTM5.4970.000
TTM5.497YOY7.663-2.166
TTM5.4975Y6.126-0.630
5Y6.12610Y5.696+0.430
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4973.905+1.592
TTM5.4974.212+1.285
YOY7.6635.337+2.326
5Y6.1266.062+0.064
10Y5.6966.401-0.705
1.3.2. Quick Ratio

Measures if I-Mab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare I-Mab to the Biotechnology industry mean.
  • A Quick Ratio of 5.71 means the company can pay off $5.71 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of I-Mab:

  • The MRQ is 5.707. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.707. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.707TTM5.7070.000
TTM5.707YOY8.826-3.119
TTM5.7075Y6.427-0.720
5Y6.42710Y6.077+0.350
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.7073.572+2.135
TTM5.7074.001+1.706
YOY8.8265.364+3.462
5Y6.4276.009+0.418
10Y6.0776.287-0.210

1.4. Solvency of I-Mab.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of I-Mab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare I-Mab to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.26 means that I-Mab assets are financed with 26.2% credit (debt) and the remaining percentage (100% - 26.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of I-Mab:

  • The MRQ is 0.262. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.262. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.262TTM0.2620.000
TTM0.262YOY0.185+0.076
TTM0.2625Y0.826-0.565
5Y0.82610Y0.904-0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2620.336-0.074
TTM0.2620.334-0.072
YOY0.1850.271-0.086
5Y0.8260.366+0.460
10Y0.9040.389+0.515
1.4.2. Debt to Equity Ratio

Measures if I-Mab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare I-Mab to the Biotechnology industry mean.
  • A Debt to Equity ratio of 35.4% means that company has $0.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of I-Mab:

  • The MRQ is 0.354. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.354. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.354TTM0.3540.000
TTM0.354YOY0.227+0.127
TTM0.3545Y0.141+0.213
5Y0.14110Y0.118+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3540.382-0.028
TTM0.3540.397-0.043
YOY0.2270.341-0.114
5Y0.1410.432-0.291
10Y0.1180.465-0.347

2. Market Valuation of I-Mab

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings I-Mab generates.

  • Above 15 is considered overpriced but always compare I-Mab to the Biotechnology industry mean.
  • A PE ratio of -1.04 means the investor is paying $-1.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of I-Mab:

  • The EOD is -0.446. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.036. Based on the earnings, the company is expensive. -2
  • The TTM is -1.036. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.446MRQ-1.036+0.590
MRQ-1.036TTM-1.0360.000
TTM-1.036YOY-11.878+10.842
TTM-1.0365Y9.119-10.155
5Y9.11910Y7.599+1.520
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.446-2.262+1.816
MRQ-1.036-2.599+1.563
TTM-1.036-2.674+1.638
YOY-11.878-4.133-7.745
5Y9.119-6.258+15.377
10Y7.599-6.171+13.770
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of I-Mab:

  • The EOD is -0.936. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.174. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.174. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.936MRQ-2.174+1.238
MRQ-2.174TTM-2.1740.000
TTM-2.174YOY-27.610+25.435
TTM-2.1745Y6.993-9.167
5Y6.99310Y5.827+1.165
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.936-2.913+1.977
MRQ-2.174-3.275+1.101
TTM-2.174-3.508+1.334
YOY-27.610-5.620-21.990
5Y6.993-8.306+15.299
10Y5.827-8.854+14.681
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of I-Mab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.83 means the investor is paying $0.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of I-Mab:

  • The EOD is 0.358. Based on the equity, the company is cheap. +2
  • The MRQ is 0.830. Based on the equity, the company is cheap. +2
  • The TTM is 0.830. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.358MRQ0.830-0.473
MRQ0.830TTM0.8300.000
TTM0.830YOY6.036-5.206
TTM0.8305Y2.353-1.522
5Y2.35310Y1.960+0.392
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3581.858-1.500
MRQ0.8302.090-1.260
TTM0.8302.091-1.261
YOY6.0362.866+3.170
5Y2.3533.488-1.135
10Y1.9603.836-1.876
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of I-Mab.

3.1. Institutions holding I-Mab

Institutions are holding 42.028% of the shares of I-Mab.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Hillhouse Capital Advisors, Ltd.8.56140.2645690922000
2023-12-31Two Sigma Investments LLC0.71240.002557490111017523.7075
2023-12-31Temasek Holdings Ltd.0.70220.00656665000
2023-12-31Two Sigma Advisers, LLC0.69230.002555870014720035.7716
2023-12-31GSA Capital Partners LLP0.66680.0859538119342573175.1879
2023-12-31Morgan Stanley - Brokerage Accounts0.64030.0001516696-471985-47.7389
2023-12-31Canada Pension Plan Investment Board0.38860.0008313600267558581.1172
2023-09-30International Biotechnology Trust PLC0.38470.138131049900
2023-12-31Schroder Investment Management Group0.38470.00083104993104990
2023-12-31Goldman Sachs Group Inc0.35980.00012903904901920.3086
2023-12-31EDBI Pte Ltd0.27530.417622213600
2023-12-31Millennium Management LLC0.2370.0002191301-363445-65.5156
2023-12-31Barclays PLC0.21440.00011730646059753.8798
2023-12-31abrdn PLC0.20150.00071625801625800
2023-12-31Acadian Asset Management LLC0.19280.00111555722727321.2574
2023-12-31Man Group PLC0.13710.00061106241106240
2023-12-31State Street Corporation0.126010169921742.1844
2023-12-31BlackRock Inc0.1240100065-623215-86.1651
2023-12-31Diametric Capital, LP0.1230.114899295-23658-19.2415
2023-12-31Alberta Investment Management Corp0.09260.00137472300
Total 15.21691.037712280333+107969+0.9%

3.2. Funds holding I-Mab

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31International Biotechnology Ord0.38470.16631049900
2024-03-28Invesco Golden Dragon China ETF0.07710.076962185-612-0.9746
2024-02-29abrdn Healthcare Investors0.06680.00965388500
2024-02-29abrdn Healthcare Opportunities0.05420.00694373800
2024-03-28SPDR® Portfolio Emerging Markets ETF0.050.00094033400
2024-02-29abrdn World Healthcare0.04810.01183884800
2024-02-29Fidelity Nasdaq Composite Index0.04260.00043434700
2023-12-31Fullgoal Glb Healt Life Alloc(QDII)RMB0.03720.25343000000
2024-03-28SPDR® S&P China ETF0.03490.01092816400
2024-02-29abrdn Life Sciences Investors0.03240.01052610900
2024-03-28Invesco NASDAQ Future Gen 200 ETF0.02860.52772306100
2024-02-29DFA Emerging Markets Social Core Port0.02340.00221890900
2024-02-29Dimensional Emerg Mkt Trgtd Val USD Acc0.0180.00581450100
2023-09-11FT FTP Emerging Markets Strength 4 CA0.01220.150598332993.1361
2023-09-11FT Emerging Markets Strength 53 CA0.01210.1598052963.1128
2024-02-29DFA Em Mkts Sustnby Cor 1 Instl0.01150.0017930600
2023-09-30Blackstone Alternative Multi-Strategy I0.00880.000271003004.4118
2023-12-31VL China Fund A0.00770.0907620062000
2023-06-30BSF BKL Systematic APAC Eq AR Z2 USD0.00710.0344573057300
2024-03-28SPDR® S&P Emerging Markets Small Cap ETF0.00680.0012547200
Total 0.96421.5117778026+12213+1.6%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of I-Mab compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.816-2.8160%-1.779-37%1.110-354%0.839-436%
Book Value Per Share--5.0355.0350%7.851-36%3.480+45%2.814+79%
Current Ratio--5.4975.4970%7.663-28%6.126-10%5.696-3%
Debt To Asset Ratio--0.2620.2620%0.185+41%0.826-68%0.904-71%
Debt To Equity Ratio--0.3540.3540%0.227+56%0.141+151%0.118+201%
Dividend Per Share----0%-0%0.005-100%0.004-100%
Eps---4.036-4.0360%-3.990-1%-2.090-48%-1.827-55%
Free Cash Flow Per Share---1.922-1.9220%-1.716-11%-0.984-49%-0.898-53%
Free Cash Flow To Equity Per Share---1.851-1.8510%-0.700-62%0.969-291%0.946-296%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---14.495--------
Intrinsic Value_10Y_min---18.009--------
Intrinsic Value_1Y_max---1.077--------
Intrinsic Value_1Y_min---1.203--------
Intrinsic Value_3Y_max---3.521--------
Intrinsic Value_3Y_min---4.158--------
Intrinsic Value_5Y_max---6.311--------
Intrinsic Value_5Y_min---7.684--------
Market Cap145262880.000-137%344917774.520344917774.5200%3824448824.000-91%1594889407.704-78%1329074506.420-74%
Net Profit Margin--10.88510.8850%-26.487+343%-14.256+231%-16.182+249%
Operating Margin--8.4588.4580%-23.531+378%-14.169+268%-16.028+289%
Operating Ratio---7.458-7.4580%24.531-130%15.385-148%17.040-144%
Pb Ratio0.358-132%0.8300.8300%6.036-86%2.353-65%1.960-58%
Pe Ratio-0.446+57%-1.036-1.0360%-11.878+1047%9.119-111%7.599-114%
Price Per Share1.800-132%4.1804.1800%47.390-91%19.744-79%16.453-75%
Price To Free Cash Flow Ratio-0.936+57%-2.174-2.1740%-27.610+1170%6.993-131%5.827-137%
Price To Total Gains Ratio-0.639+57%-1.484-1.4840%-26.645+1695%-8.179+451%-8.179+451%
Quick Ratio--5.7075.7070%8.826-35%6.427-11%6.077-6%
Return On Assets---0.592-0.5920%-0.414-30%-0.388-35%-0.372-37%
Return On Equity---0.802-0.8020%-0.508-37%-0.245-69%-0.204-75%
Total Gains Per Share---2.816-2.8160%-1.779-37%1.115-353%0.843-434%
Usd Book Value--415449820.600415449820.6000%633574627.600-34%282648386.160+47%228640040.217+82%
Usd Book Value Change Per Share---2.816-2.8160%-1.779-37%1.110-354%0.839-436%
Usd Book Value Per Share--5.0355.0350%7.851-36%3.480+45%2.814+79%
Usd Dividend Per Share----0%-0%0.005-100%0.004-100%
Usd Eps---4.036-4.0360%-3.990-1%-2.090-48%-1.827-55%
Usd Free Cash Flow---158626493.500-158626493.5000%-138517752.500-13%-80137966.140-49%-73053311.850-54%
Usd Free Cash Flow Per Share---1.922-1.9220%-1.716-11%-0.984-49%-0.898-53%
Usd Free Cash Flow To Equity Per Share---1.851-1.8510%-0.700-62%0.969-291%0.946-296%
Usd Market Cap145262880.000-137%344917774.520344917774.5200%3824448824.000-91%1594889407.704-78%1329074506.420-74%
Usd Price Per Share1.800-132%4.1804.1800%47.390-91%19.744-79%16.453-75%
Usd Profit---333072618.200-333072618.2000%-321985812.100-3%-169314024.880-49%-147959511.400-56%
Usd Revenue---30597850.300-30597850.3000%12156390.600-352%41234229.440-174%34627838.467-188%
Usd Total Gains Per Share---2.816-2.8160%-1.779-37%1.115-353%0.843-434%
 EOD+3 -5MRQTTM+0 -0YOY+6 -275Y+12 -2310Y+12 -23

4.2. Fundamental Score

Let's check the fundamental score of I-Mab based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.446
Price to Book Ratio (EOD)Between0-10.358
Net Profit Margin (MRQ)Greater than010.885
Operating Margin (MRQ)Greater than08.458
Quick Ratio (MRQ)Greater than15.707
Current Ratio (MRQ)Greater than15.497
Debt to Asset Ratio (MRQ)Less than10.262
Debt to Equity Ratio (MRQ)Less than10.354
Return on Equity (MRQ)Greater than0.15-0.802
Return on Assets (MRQ)Greater than0.05-0.592
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of I-Mab based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.507
Ma 20Greater thanMa 501.819
Ma 50Greater thanMa 1001.785
Ma 100Greater thanMa 2001.771
OpenGreater thanClose1.810
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Gross Profit  7,427-3,2844,143208,899213,042-207,2985,744-40,103-34,359
Total Revenue 7,427-3,2844,143208,899213,042-200,88612,156-42,754-30,598



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,073,665
Total Liabilities1,065,339
Total Stockholder Equity3,008,326
 As reported
Total Liabilities 1,065,339
Total Stockholder Equity+ 3,008,326
Total Assets = 4,073,665

Assets

Total Assets4,073,665
Total Current Assets3,626,476
Long-term Assets447,189
Total Current Assets
Cash And Cash Equivalents 3,214,005
Short-term Investments 235,429
Net Receivables 80,278
Inventory -80,278
Other Current Assets 177,042
Total Current Assets  (as reported)3,626,476
Total Current Assets  (calculated)3,626,476
+/-0
Long-term Assets
Property Plant Equipment 123,966
Goodwill 162,574
Long Term Investments 30,850
Intangible Assets 118,888
Long-term Assets Other 10,911
Long-term Assets  (as reported)447,189
Long-term Assets  (calculated)447,189
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities659,742
Long-term Liabilities405,597
Total Stockholder Equity3,008,326
Total Current Liabilities
Short-term Debt 42,917
Short Long Term Debt 18,956
Other Current Liabilities 608,148
Total Current Liabilities  (as reported)659,742
Total Current Liabilities  (calculated)670,021
+/- 10,279
Long-term Liabilities
Capital Lease Obligations 56,030
Long-term Liabilities Other 16,963
Long-term Liabilities  (as reported)405,597
Long-term Liabilities  (calculated)72,993
+/- 332,604
Total Stockholder Equity
Common Stock132
Retained Earnings -6,766,655
Accumulated Other Comprehensive Income 216,723
Other Stockholders Equity 9,558,126
Total Stockholder Equity (as reported)3,008,326
Total Stockholder Equity (calculated)3,008,326
+/-0
Other
Capital Stock132
Cash and Short Term Investments 3,449,434
Common Stock Shares Outstanding 82,516
Current Deferred Revenue8,677
Liabilities and Stockholders Equity 4,073,665
Net Debt -3,139,019
Net Invested Capital 3,027,282
Net Working Capital 2,966,734
Property Plant and Equipment Gross 123,966
Short Long Term Debt Total 74,986



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
> Total Assets 
1,025,345
2,375,938
1,737,572
6,333,793
5,629,431
4,073,665
4,073,6655,629,4316,333,7931,737,5722,375,9381,025,345
   > Total Current Assets 
691,591
2,036,861
1,361,319
5,343,664
4,781,718
3,626,476
3,626,4764,781,7185,343,6641,361,3192,036,861691,591
       Cash And Cash Equivalents 
307,930
1,588,278
1,137,473
4,758,778
3,523,632
3,214,005
3,214,0053,523,6324,758,7781,137,4731,588,278307,930
       Short-term Investments 
266,245
255,958
32,000
31,530
753,164
235,429
235,429753,16431,53032,000255,958266,245
       Net Receivables 
4,101
23,906
55,870
553,356
477,685
80,278
80,278477,685553,35655,87023,9064,101
       Other Current Assets 
113,315
168,719
191,846
422,858
444,604
177,042
177,042444,604422,858191,846168,719113,315
   > Long-term Assets 
333,754
339,077
376,253
990,129
847,713
447,189
447,189847,713990,129376,253339,077333,754
       Property Plant Equipment 
22,336
27,659
46,504
40,269
158,497
123,966
123,966158,49740,26946,50427,65922,336
       Goodwill 
162,574
162,574
162,574
162,574
162,574
162,574
162,574162,574162,574162,574162,574162,574
       Long Term Investments 
0
0
0
664,832
380,342
30,850
30,850380,342664,832000
       Intangible Assets 
148,844
148,844
148,844
120,444
119,666
118,888
118,888119,666120,444148,844148,844148,844
       Other Assets 
0
0
18,331
2,010
26,634
0
026,6342,01018,33100
> Total Liabilities 
1,325,140
3,331,042
3,772,267
706,648
1,041,635
1,065,339
1,065,3391,041,635706,6483,772,2673,331,0421,325,140
   > Total Current Liabilities 
195,144
346,158
588,479
576,125
624,004
659,742
659,742624,004576,125588,479346,158195,144
       Short-term Debt 
99,000
80,000
56,807
8,058
30,669
42,917
42,91730,6698,05856,80780,00099,000
       Short Long Term Debt 
99,000
80,000
50,000
0
0
18,956
18,9560050,00080,00099,000
       Accounts payable 
14,509
67,674
-3,920
0
-2,369
0
0-2,3690-3,92067,67414,509
       Other Current Liabilities 
65,832
184,333
531,672
560,558
593,335
608,148
608,148593,335560,558531,672184,33365,832
   > Long-term Liabilities 
1,129,996
2,984,884
3,183,788
130,523
417,631
405,597
405,597417,631130,5233,183,7882,984,8841,129,996
       Long term Debt Total 
114,007
67,026
68,199
0
0
0
00068,19967,026114,007
       Long term Debt 
114,007
67,026
68,199
0
0
0
00068,19967,026114,007
       Capital Lease Obligations 
0
0
14,299
13,600
112,455
56,030
56,030112,45513,60014,29900
       Other Liabilities 
0
2,500
3,920
124,981
335,845
0
0335,845124,9813,9202,5000
       Long-term Liabilities Other 
0
0
0
8,975
14,934
16,963
16,96314,9348,975000
> Total Stockholder Equity
-299,795
-955,104
-2,034,695
5,627,145
4,587,796
3,008,326
3,008,3264,587,7965,627,145-2,034,695-955,104-299,795
   Common Stock
6
6
6
114
126
132
132126114666
   Retained Earnings -6,766,655-4,354,833-2,023,292-2,494,207-1,014,489-357,860
   Accumulated Other Comprehensive Income 
5,691
59,380
70,127
-50,793
-186,510
216,723
216,723-186,510-50,79370,12759,3805,691
   Capital Surplus 
52,369
0
389,379
0
0
0
000389,379052,369
   Treasury Stock0000-1-1



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue-221,563
Cost of Revenue-27,237
Gross Profit-248,800-248,800
 
Operating Income (+$)
Gross Profit-248,800
Operating Expense-1,625,172
Operating Income-1,873,972-1,873,972
 
Operating Expense (+$)
Research Development904,901
Selling General Administrative720,271
Selling And Marketing Expenses-
Operating Expense1,625,1721,625,172
 
Net Interest Income (+$)
Interest Income26,908
Interest Expense-9
Other Finance Cost-0
Net Interest Income26,899
 
Pretax Income (+$)
Operating Income-1,873,972
Net Interest Income26,899
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-2,411,125-1,336,819
EBIT - interestExpense = -1,873,981
-2,411,125
-2,411,813
Interest Expense9
Earnings Before Interest and Taxes (EBIT)-1,873,972-2,411,116
Earnings Before Interest and Taxes (EBITDA)-2,411,116
 
After tax Income (+$)
Income Before Tax-2,411,125
Tax Provision-697
Net Income From Continuing Ops-2,411,822-2,411,822
Net Income-2,411,822
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,652,409
Total Other Income/Expenses Net-537,153-26,899
 

Technical Analysis of I-Mab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of I-Mab. The general trend of I-Mab is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine I-Mab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of I-Mab.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.87 < 1.925 < 1.94.

The bearish price targets are: 1.755 > 1.7 > 1.63.

Tweet this
I-Mab Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of I-Mab. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

I-Mab Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of I-Mab. The current macd is -0.00246806.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the I-Mab price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for I-Mab. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the I-Mab price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
I-Mab Daily Moving Average Convergence/Divergence (MACD) ChartI-Mab Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of I-Mab. The current adx is 7.05368196.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy I-Mab shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
I-Mab Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of I-Mab. The current sar is 1.92815358.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
I-Mab Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of I-Mab. The current rsi is 48.51. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
I-Mab Daily Relative Strength Index (RSI) ChartI-Mab Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of I-Mab. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the I-Mab price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
I-Mab Daily Stochastic Oscillator ChartI-Mab Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of I-Mab. The current cci is -76.57700173.

I-Mab Daily Commodity Channel Index (CCI) ChartI-Mab Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of I-Mab. The current cmo is -7.31354947.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
I-Mab Daily Chande Momentum Oscillator (CMO) ChartI-Mab Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of I-Mab. The current willr is -63.63636364.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that I-Mab is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
I-Mab Daily Williams %R ChartI-Mab Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of I-Mab.

I-Mab Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of I-Mab. The current atr is 0.07488579.

I-Mab Daily Average True Range (ATR) ChartI-Mab Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of I-Mab. The current obv is -10,563,736.

I-Mab Daily On-Balance Volume (OBV) ChartI-Mab Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of I-Mab. The current mfi is 58.23.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
I-Mab Daily Money Flow Index (MFI) ChartI-Mab Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for I-Mab.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

I-Mab Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of I-Mab based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.507
Ma 20Greater thanMa 501.819
Ma 50Greater thanMa 1001.785
Ma 100Greater thanMa 2001.771
OpenGreater thanClose1.810
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of I-Mab with someone you think should read this too:
  • Are you bullish or bearish on I-Mab? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about I-Mab? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about I-Mab

I send you an email if I find something interesting about I-Mab.


Comments

How you think about this?

Leave a comment

Stay informed about I-Mab.

Receive notifications about I-Mab in your mailbox!